Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

Recruiting

PIROutcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

Sponsor:

Well Cell Global

Code:

NCT07187479

Conditions

Chronic Kidney Disease (Stages 4 and 5)

Kidney Disease

Type 2 Diabetes

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Physiologic Insulin Resensitization (PIR)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-22. This information was provided to ClinicalTrials.gov by Well Cell Global on 2025-10-20.